MDACC Study No:2008-0210 ( NCT No: NCT01013441)
Title:Trial of immune reconstitution with CD3/CD28 bead activated T-cells following chemo-immunotherapy in patients with chronic lymphocytic leukemia.
Principal Investigator:Chitra M. Hosing
Treatment Agent:T cell therapy
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if giving T-cells (immune
cells) that have been specially processed in the laboratory will help CLL
patients' immune system recover faster after chemotherapy. This may help lower
the chance of infections. The safety of this treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:T cell therapy
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:NA
Supported By:CLL Global Research Foundation
Return Visit:Patients who receive alemtuzumab based therapy may have to come back every 2
weeks till the alemtuzumab levels become undetectable.
All patients will come back for follow up at 30, 90 days and 1 year after the
infusion of T cells.
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Chitra M. Hosing
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults